Holen Sie sich die Stockscreener-App
210.23
1.95%
-4.19
Handel nachbörslich:
210.50
0.27
+0.13%
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
Jim Cramer Gives Green Light To This Health Care Stock - Benzinga
Jazz Pharmaceuticals (JAZZ) President & CEO Renee Gala Sells 2,0 - GuruFocus
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Zacks Investment Research
Jazz Pharmaceuticals plc (J7Z.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
The top 12 companies hiring in biopharma now - BioSpace
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks - Yahoo Finance
What Comes Next for Jazz Pharmaceuticals (NASDAQ:JAZZ)? - Kalkine Media
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - Yahoo Finance
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com UK
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - tradingview.com
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead - Yahoo Finance
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com UK
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com Canada
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com UK
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com South Africa
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Canada
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - investing.com
0.27%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):